PreciseDx has shared an update. The company announced that three scientific presentations at the upcoming San Antonio Breast Cancer Symposium (SABCS25) will feature new data on PreciseBreast, its AI-powered digital pathology test designed to assess breast cancer risk of recurrence. The accepted abstracts cover use of the test on biopsy specimens to predict recurrence, an AI-enabled phenotyping approach for triple-negative breast cancer, and a real-world evaluation of PreciseBreast for risk stratification in early-stage invasive breast cancer in collaboration with Lankenau Medical Center/Main Line Health.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, multiple peer-reviewed presentations at a major oncology conference signal ongoing clinical validation efforts and growing academic engagement around PreciseDx’s technology. Positive or strengthening data could enhance the clinical credibility and adoption prospects of PreciseBreast, potentially supporting future reimbursement decisions and commercial partnerships with healthcare systems and pathology labs. The real-world evaluation, in particular, is relevant for demonstrating utility outside of controlled trial settings, which may be important for payors and hospital decision-makers. While the LinkedIn post does not disclose financial figures or commercial agreements, increased scientific visibility at SABCS25 may improve the company’s competitive position in the AI-driven digital pathology and oncology diagnostics market and could be a precursor to broader commercialization or strategic collaborations.